Greg Reh
Greg is a US Consulting Principal, with more than 27 years of experience in the life sciences, process manufacturing, consumer, and government sectors. His consulting career has spanned topics such as technology strategy, integration solution development, and implementation of emerging and disruptive technology.
Greg’s clients have included multinational pharmaceutical, biotechnology and chemical manufacturing organizations where he successfully led consulting services in support of regulatory, clinical, commercialization and manufacturing operations.
Articles: Greg Reh
Forging a New Path to Commercialization for Cell and Gene Therapies
Opinion / Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which present unique challenges to pharma…
Megatrends from the 2019 Deloitte Life Sciences Outlook
Opinion / Deloitte’s Global Life Sciences & Health Care industry leader, Greg Reh gives us an exclusive insight into their forecast for 2019’s industry trends. For companies to address mounting pressures, a digital-first mindset will be required to make business operations more efficient and bring transformational therapies to the market. Digital transformation will continue to be…
Latest Report
